Objective: Alzheimer's disease (AD) shows less autonomic dysfunction. There was a lack of response or prolongation of its latency in skin sympathetic response. Vinpocetine is a classic inhibitor of PDE1 activity. Vinpocetine treatment has been shown to enhance performance on cognitive tests in humans. The efficacy of the use of vinpocetine in clinical trials has been controversial. A comparison of multiple studies evaluating vinpocetine use in AD was recently conducted. Our first aim was to assess dysautonomia in rat with AD electrophysiologically, using sympathetic skin response (SSR) test. The second aim of this study, evaluate the effect of vinpocetine treatment on Alzheimer autonomic dysfunction and attention deficiency.